Comparing the cost-effectiveness of linezolid to trimethoprim/sulfamethoxazole plus rifampicin for the treatment of methicillin-resistant Staphylococcus aureus infection: a healthcare system perspective
Published inClinical Microbiology and Infection, vol. 23, no. 9, p. 659-666
Publication date2017
Abstract
Affiliation
Citation (ISO format)
VON DACH, Elodie et al. Comparing the cost-effectiveness of linezolid to trimethoprim/sulfamethoxazole plus rifampicin for the treatment of methicillin-resistant Staphylococcus aureus infection: a healthcare system perspective. In: Clinical Microbiology and Infection, 2017, vol. 23, n° 9, p. 659–666. doi: 10.1016/j.cmi.2017.02.011
Main files (1)
Article (Published version)
Identifiers
- PID : unige:99033
- DOI : 10.1016/j.cmi.2017.02.011
- PMID : 28232163
ISSN of the journal1198-743X